Take a look back at our most popular biosimilars coverage for 2022.
Several provisions in the law are designed to protect and foster the biosimilar market. But some representatives of the sector see CMS drug price negotiation as a threat to profit margins.
The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics.
Some companies are using the interchangeability designation as a marketing ploy.
Pharmacy benefit managers can help health plans understand when to best leverage and align to biosimilars and other cost-effective treatments.
Circle 2023 on your calendar. That's when as many as 11 biosimilars to Humira are headed for the US market.
Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
Gaps exist in knowledge about interchangeability and substitutions.
A new report by Cardinal Health includes research findings on insulin biosimilars use among retail pharmacists and physicians.